NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CRGX

CARGO Therapeutics Inc

Jul 03 • 01:30PM ET

4.46

Dollar change +0.06
Percentage change 1.36	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP VRTX GILD NTLA BMRN PFE BLUE EDIT SGMO QURE

| Held by: VTI IWM VXF IWN IBB SCHA VTWO IWC TMAT AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.66	Insider Own	28.77%	Shs Outstand	46.05M	Perf Week	5.69%
Market Cap	205.67M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	-0.23%	Shs Float	32.85M	Perf Month	-0.89%
Enterprise Value	-82.72M	PEG	-	EPS next Q	-0.51	Inst Own	76.85%	Short Float	9.99%	Perf Quarter	5.44%
Income	-216.19M	P/S	-	EPS this Y	6.36%	Inst Trans	-16.06%	Short Ratio	4.90	Perf Half Y	-67.59%
Sales	0.00M	P/B	0.73	EPS next Y	51.48%	ROA	-55.12%	Short Interest	3.28M	Perf YTD	-69.07%
Book/sh	6.13	P/C	0.65	EPS next 5Y	32.19%	ROE	-65.94%	52W High	25.45 -82.48%	Perf Year	-72.12%
Cash/sh	6.91	P/FCF	-	EPS past 3/5Y	-188.63% -	ROIC	-69.65%	52W Low	3.00 48.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.30% 4.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.30	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.91	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.30	EPS Q/Q	-102.15%	SMA20	2.13%	Beta	0.21	Target Price	4.23
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	4.02%	Rel Volume	0.22	Prev Close	4.40
Employees	167	LT Debt/Eq	0.10	Earnings	May 14	SMA200	-56.98%	Avg Volume	669.33K	Price	4.46
IPO	Nov 10, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-95.58% -	Trades		Volume	147,922	Change	1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-30-25	Downgrade	Truist	Buy → Hold	$32 → $7
Jan-30-25	Downgrade	Piper Sandler	Overweight → Neutral	$34 → $4
Jan-30-25	Downgrade	JP Morgan	Overweight → Underweight
Jan-30-25	Downgrade	Jefferies	Buy → Hold	$32 → $3
Jan-30-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-30-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-26-24	Initiated	William Blair	Outperform
Jul-22-24	Initiated	H.C. Wainwright	Buy	$33
Jul-08-24	Initiated	Chardan Capital Markets	Buy	$28
Jun-27-24	Initiated	Piper Sandler	Overweight	$37
Dec-05-23	Initiated	Truist	Buy	$34
Dec-05-23	Initiated	TD Cowen	Outperform
Dec-05-23	Initiated	JP Morgan	Overweight	$23
Dec-05-23	Initiated	Jefferies	Buy	$28

Show Previous Ratings

Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-19-25 09:49AM	CARGO Stock Surges 19% Pre-Market After Suspending Development, Cutting 90% of Workforce (GuruFocus.com) +9.21%
06:21AM	Cargo shelves cell therapy research, lays off more staff (BioPharma Dive)
Mar-18-25 04:05PM	CARGO Therapeutics Provides Corporate Update (GlobeNewswire) -7.54%
Feb-20-25 09:35AM	After Plunging -69.58% in 4 Weeks, Here's Why the Trend Might Reverse for CARGO Therapeutics, Inc. (CRGX) (Zacks)
09:55AM	Loading…
Feb-12-25 09:55AM	Here's Why CARGO Therapeutics, Inc. (CRGX) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-03-25 12:00PM	CARGO Therapeutics, Inc. (CRGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-29-25 04:05PM	CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options (GlobeNewswire) -74.30%
Jan-10-25 08:00AM	CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025 (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire)
Dec-17-24 08:00AM	CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 06:34PM	Down -14.13% in 4 Weeks, Here's Why CARGO Therapeutics, Inc. (CRGX) Looks Ripe for a Turnaround (Zacks) +5.53%
Dec-12-24 09:55AM	Bears are Losing Control Over CARGO Therapeutics, Inc. (CRGX), Here's Why It's a 'Buy' Now (Zacks) -8.90%
Nov-12-24 04:05PM	CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.98%
Nov-05-24 04:05PM	CARGO Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:23AM	Loading…
09:23AM	CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity (GlobeNewswire)
Aug-16-24 08:53PM	CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024 (InvestorPlace) +5.61%
06:50PM	Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week (Motley Fool)
Aug-12-24 04:05PM	CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.45%
Jul-10-24 08:00AM	CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet (GlobeNewswire)
Jun-04-24 04:05PM	CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director (GlobeNewswire)
01:56PM	Hedge Fund and Insider Trading News: Bill Ackman, Jim Chanos, Daniel Loeb, Mark Yusko, Citadel LLC, CARGO Therapeutics Inc (CRGX), Apple Inc. (AAPL), and More (Insider Monkey)
May-30-24 06:00AM	Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now (InvestorPlace)
May-28-24 08:05AM	CARGO Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -14.33%
08:00AM	CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing (GlobeNewswire)
May-22-24 12:00PM	What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High? (Zacks)
May-14-24 09:54PM	CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +6.55%
04:05PM	CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-15-24 04:05PM	CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors (GlobeNewswire)
10:53PM	Loading…
Mar-21-24 10:53PM	CRGX Stock Earnings: Cargo Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.23%
04:05PM	CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 04:01PM	CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Jan-03-24 08:05AM	CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -11.58%
Dec-18-23 04:04PM	Alexandria Snags a Pair of Big Bicoastal Lab Leases (Commercial Observer) +13.88%
Dec-13-23 10:51PM	CRGX Stock Earnings: Cargo Therapeutics Reported Results for Q3 2023 (InvestorPlace)
04:05PM	CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results (GlobeNewswire)
Dec-11-23 07:53PM	3 New Stock Listings That Can Deliver Multibagger Returns (InvestorPlace) -5.55%

Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Radhakrishnan Anup	See Remarks	Jul 02 '25	Sale	4.18	1,632	6,822	120,781	Jul 03 06:57 PM
Radhakrishnan Anup	See Remarks	May 14 '25	Sale	3.84	27,404	105,272	122,413	May 16 04:19 PM
Radhakrishnan Anup	See Remarks	Apr 03 '25	Sale	4.00	1,629	6,522	77,317	Apr 08 05:04 PM
Chapman Gina	President & CEO	Sep 18 '24	Option Exercise	5.03	7,166	36,045	111,071	Sep 20 05:24 PM
Chapman Gina	President & CEO	Sep 19 '24	Option Exercise	5.03	2,975	14,964	106,880	Sep 20 05:24 PM
Chapman Gina	President & CEO	Sep 18 '24	Sale	25.09	7,166	179,775	103,905	Sep 20 05:24 PM
Chapman Gina	President & CEO	Sep 19 '24	Sale	25.03	2,975	74,457	103,905	Sep 20 05:24 PM
Radhakrishnan Anup	Chief Financial Officer	Sep 18 '24	Option Exercise	5.03	1,600	8,048	8,046	Sep 20 05:23 PM
Radhakrishnan Anup	Chief Financial Officer	Sep 18 '24	Sale	25.28	1,600	40,452	6,446	Sep 20 05:23 PM
ANUP RADHAKRISHNAN	Officer	Sep 18 '24	Proposed Sale	23.33	14,000	326,620		Sep 18 04:38 PM
GINA CHAPMAN	Director	Sep 18 '24	Proposed Sale	23.33	75,000	1,749,750		Sep 18 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRGX

CARGO Therapeutics Inc

Upgrade your FINVIZ experience